{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:18:24Z","timestamp":1777288704374,"version":"3.51.4"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Niemann-Pick disease Type C (NPC) is a genetic, incurable, neurodegenerative disorder. This orphan disease is most frequently caused by mutations in the NPC1 protein, resulting in intralysossomal cholesterol accumulation. NPC1 is found in neuronal cell bodies, axon terminals and synaptosomes, suggesting it plays a role in lysosomal degradation pathway and in synaptic transmission. Neuronal function is especially vulnerable to NPC1 deficiency and synaptic changes seem a key element in disease development. Currently, Miglustat (Zavesca\u00ae) is the only approved treatment for NPC. However, preclinical evidence showed that low-dose Efavirenz reverted synaptic defects through pharmacological activation of the enzyme CYP46.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This is a single-center, phase II clinical trial to evaluate the efficacy and safety of Efavirenz in addition to standard of care in patients diagnosed with adult or late juvenile-onset NPC with cognitive impairment. All enrolled patients will be treated orally with 25\u2009mg\/d of Efavirenz for 52 weeks (1 year). Secondary objectives include evaluating clinical (neurological and neuropsychological questionnaires) and biological (imaging and biochemical biomarkers) parameters.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>NPC is still an unmet medical need. Although different therapeutic approaches are under study, this is the first clinical trial (to the best of our knowledge) studying the effects of Efavirenz in adult- and late-juvenile-onset NPC. Despite the small sample size and the single-arm design, we expect the results to show Efavirenz\u2019s capacity of activating the CYP46 enzyme to compensate for NPC1 deficiency and correct synaptic changes, therefore compensating cognitive and psychiatric changes in these patients. This study may provide direct benefit to enrolled patients in terms of slowing down the disease progression.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000031471","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T16:00:57Z","timestamp":1670515257000},"page":"e31471","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety clinical trial with efavirenz in patients diagnosed with adult Niemann-pick type C with cognitive impairment"],"prefix":"10.1097","volume":"101","author":[{"given":"Jordi","family":"Gasc\u00f3n-Bayarri","sequence":"first","affiliation":[{"name":"Neurology Department, Bellvitge University Hospital, L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Adult Lysosomal Diseases Clinical Expertise Unit, Bellvitge University Hospital, L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Department of Morphological Sciences, School of Medicine, Autonomous University of Barcelona, Bellaterra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petru Cristian","family":"Simon","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roser","family":"Llop","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3353-5186","authenticated-orcid":false,"given":"Thiago","family":"Carnaval","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, IDIBELL, University of Barcelona, L\u2019Hospitalet DE Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Ledesma","sequence":"additional","affiliation":[{"name":"Severo Ochoa Molecular Biology Center (CSIC-UAM), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imma","family":"Rico","sequence":"additional","affiliation":[{"name":"Neurology Department, Bellvitge University Hospital, L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet DE Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"S\u00e1nchez-Casta\u00f1eda","sequence":"additional","affiliation":[{"name":"Neurology Department, Bellvitge University Hospital, L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Department of Clinical Psychology and Psychobiology, Neurosciences Institute, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Campdelacreu-Fumad\u00f3","sequence":"additional","affiliation":[{"name":"Neurology Department, Bellvitge University Hospital, L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet DE Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahum","family":"Calvo-Malvar","sequence":"additional","affiliation":[{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Neuroradiology Department, Bellvitge University Hospital, L\u2019Hospitalet DE Llobregat, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f2nica","family":"Cos","sequence":"additional","affiliation":[{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Neuroradiology Department, Bellvitge University Hospital, L\u2019Hospitalet DE Llobregat, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"de Lama","sequence":"additional","affiliation":[{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Neuroradiology Department, Bellvitge University Hospital, L\u2019Hospitalet DE Llobregat, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Cort\u00e9s-Romera","sequence":"additional","affiliation":[{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Nuclear Medicine-PET\/CT Department (IDI). Bellvitge University Hospital, L\u2019Hospitalet DE Llobregat, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rodr\u00edguez-Bel","sequence":"additional","affiliation":[{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Nuclear Medicine-PET\/CT Department (IDI). Bellvitge University Hospital, L\u2019Hospitalet DE Llobregat, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"P\u00e9rez-Sousa","sequence":"additional","affiliation":[{"name":"Neurology Department, A Coru\u00f1a University Hospital Complex, A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Cerd\u00e1n S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Neurology Department, Santa Luc\u00eda-Santa Mar\u00eda Rosell University Hospital, Cartagena, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Muelas","sequence":"additional","affiliation":[{"name":"Neurology Department, La Fe University and Polytechnical Hospital, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Sevillano","sequence":"additional","affiliation":[{"name":"Neurology Department, Salamanca University Hospital, Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Mir","sequence":"additional","affiliation":[{"name":"Movement Disorders Unit, Neurology and Clinical Neurophysiology Department, Seville Biomedical Institute, Virgen del Roc\u00edo University Hospital\/CSIC\/University of Seville, Seville, Spain"},{"name":"Neurodegenerative Diseases Network of Biomedical Research Centers (CIBERNED), Madrid, Spain"},{"name":"Medicine Departament, School of Medicine, University of Seville, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"L\u00f3pez de Munain","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Network of Biomedical Research Centers (CIBERNED), Madrid, Spain"},{"name":"Neurology Department, Donostia-Osakidetza University Hospital, San Sebastian, Spain"},{"name":"Neuroscience Department, Biodonostia Institute, San Sebastian, Spain"},{"name":"Neuroscience Department, University of the Basque Country, San Sebastian, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ferrer","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n","family":"Videla","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, Barcelona, Spain"},{"name":"Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, IDIBELL, University of Barcelona, L\u2019Hospitalet DE Llobregat, Barcelona, Spain"},{"name":"Clinical Research Support Unit (HUB-IDIBELL: Bellvitge University Hospital & Bellvitge Biomedical Research Institute), Clinical Pharmacology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1073\/pnas.55.2.366","article-title":"The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease.","volume":"55","author":"Brady","year":"1966","journal-title":"Proc Natl Acad Sci USA"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/mgme.1999.2882","article-title":"Niemann-Pick C1 is a late endosome-resident protein that transiently associates with lysosomes and the trans-Golgi network.","volume":"68","author":"Higgins","year":"1999","journal-title":"Mol Genet Metab"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1073\/pnas.96.3.805","article-title":"Niemann-Pick C1 protein: obligatory roles for N-terminal domains and lysosomal targeting in cholesterol mobilization.","volume":"96","author":"Watari","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1194\/jlr.R047837","article-title":"Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin.","volume":"55","author":"Vance","year":"2014","journal-title":"J Lipid Res"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1083\/jcb.119.1.123","article-title":"Axonal and dendritic endocytic pathways in cultured neurons.","volume":"119","author":"Parton","year":"1992","journal-title":"J Cell Biol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1074\/jbc.M205406200","article-title":"Trafficking of cholesterol from cell bodies to distal axons in Niemann Pick C1-deficient neurons.","volume":"278","author":"Karten","year":"2003","journal-title":"J Biol Chem"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1194\/jlr.M500482-JLR200","article-title":"The Niemann-Pick C1 protein in recycling endosomes of presynaptic nerve terminals.","volume":"47","author":"Karten","year":"2006","journal-title":"J Lipid Res"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1083\/jcb.201407122","article-title":"LTP-triggered cholesterol redistribution activates Cdc42 and drives AMPA receptor synaptic delivery.","volume":"208","author":"Brachet","year":"2015","journal-title":"J Cell Biol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.neurobiolaging.2010.06.001","article-title":"Cellular stress from excitatory neurotransmission contributes to cholesterol loss in hippocampal neurons aging in vitro.","volume":"32","author":"Sodero","year":"2011","journal-title":"Neurobiol Aging"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/emboj.2012.31","article-title":"Cholesterol loss during glutamate-mediated excitotoxicity.","volume":"31","author":"Sodero","year":"2012","journal-title":"EMBO J"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/hmg\/ddr505","article-title":"A novel mouse model of Niemann-Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations.","volume":"21","author":"Maue","year":"2012","journal-title":"Hum Mol Genet"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e48143","DOI":"10.15252\/embr.201948143","article-title":"NPC1 enables cholesterol mobilization during long-term potentiation that can be restored in Niemann-Pick disease type C by CYP46A1 activation.","volume":"20","author":"Mitroi","year":"2019","journal-title":"EMBO Rep"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1074\/jbc.M113.532846","article-title":"Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.","volume":"289","author":"Mast","year":"2014","journal-title":"J Biol Chem"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials.","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:31:15Z","timestamp":1746333075000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":15,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031471","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]}}}